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Abstract
Background: The interest of the case lies in an unexpected delayed bleeding following an endoscopic procedure
in a patient with post-polycythemia myelofibrosis. The case gives the opportunity to discuss the medical
management and monitoring of patients with myeloproliferative disorders undergoing minimally invasive surgery
interventions.
Case presentation: A 75 years old woman affected by post-polycythemia myelofibrosis underwent endoscopy
polypectomy followed by a delayed major local bleeding. At the time of the endoscopy followed by bleeding, the
platelet count was 837 × 109/L, haemoglobin 113 g/L, PCV 35,2% and WBC 20.22 × 106/L. No antithrombotic
prophylaxis with low molecular weight heparin was used. Antiplatelet drug was withdraw seven days before
endoscopy and restarted one week after the procedure. Polyp size was 11x19 mm and it was located on right side
of the colon.
Fourteen days after procedure the patient developed a severe lower intestinal bleeding, which required RBC
transfusion; the bleeding was in the site of polypectomy as demonstrated by arteriography; selective embolization
of the three branches of the ileo-colic artery resolve the haemorrhage.
Conclusion: There are some patients in whom current guidelines do not apply and our case stress the importance
of myeloproliferative neoplasms as a risk factor for complications of endoscopic polypectomy. The delayed
haemorrhage we observed suggest to strictly control the patient for a period longer than only one week also in
case of antithrombotic treatment with antiplatelet drugs.
Introduction
Endoscopic procedures are known to be a possible cause
of significant or uncontrolled bleeding. High-risk proce-
dures are considered those which have a risk of major
bleeding higher than 1% [1].
The National Cancer Institute Common Terminology
Criteria for Averse Events [2] defined as major bleeding
those requesting hospitalization, transfusion support or
a new surgical intervention. Polypectomy is generally
considered a high-risk procedure: the overall incidence
of clinically significant post-polypectomy bleeding may
range from 0.2 to 1.6/1000 in large scale reports [3].
Haemorrhage may occur during (immediate bleeding)
or some after (delayed bleeding) the procedure. Usually,
the delayed bleeding which complicates 0.3-0.6% of
polypectomies [4] occurs 3-7 days after the procedure,
even if a haemorrhage occurred 29 days after polypect-
omy as been described [5].
The use of antithrombotic drugs complicates the man-
agement of gastrointestinal bleeding: in particular, post-
endoscopic haemorrhages have been reported to occur in
6.1/1000 patients treated with aspirin [3]. However,
recent guidelines [1] state that no adjustment in anticoa-
gulation or antiplatelet therapy need to be made for low-
risk procedures, irrespective of the underlying condition.
In particular cases, antiplatelet drug withdraw 7-10 days
before and resumed next day the procedure should be
indicated, but the evidence is low [1]. While resuming
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anticoagulant therapy is associated with increased risk of
severe delayed post-polypectomy bleeding, this seems not
be the case with aspirin [6]. The larger polyp and those
on the right site of the colon are those at higher risk of
bleeding [7]. Other factors may also influence the risk of
bleeding after polypectomy. Older age has been shown to
be associated with increased risk [8] requesting increased
risk of transfusion. Moreover, a special attention has to
be given in some particular diseases, i.e. hemostatic mye-
loproliferative neoplasms, which have “per se” an
increased risk of mucosal bruising. However, there are
limited data assessing the bleeding risk of specific proce-
dures in these settings and specifically no data have been
found in patients with chronic myeloproliferative neo-
plasms (MPN). These diseases mainly affect people in
middle-advanced age and many cases are diagnosed after
70 years.
The interest of the case lies in an unexpected delayed
bleeding following an endoscopic procedure in a patient
with post-polycythemia myelofibrosis. The case gives the
opportunity to discuss the medical management and
monitoring of patients with myeloproliferative neoplasms
undergoing minimally invasive surgery interventions.
Case presentation
A 75 years old woman underwent endoscopy polypect-
omy followed by a delayed major local bleeding. The his-
tory of the patients was characterized by polycythemia
vera diagnosed in 1998. The patient was regularly fol-
lowed in a haematological committed center for myelo-
proliferative neoplasms and treated with phlebotomies,
low-dose aspirin and hydroyurea. In 2006 the presence of
JAK2V617F mutation was demonstrated (allele burden
97%). The year later, increased WBC, presence of some
immature circulating myeloid cells and a slight decrease
in haemoglobin were observed together with an increased
spleen volume suggesting a transformation into myelofi-
brosis. The clinical hypothesis was confirmed [9] with the
observation of leukoerithroblastic peripheral blood
picture and fibrosis grade 3 (on scale 0-3) in the bone
marrow biopsy specimen,. Moreover, the CD34 cells in
blood were 35 × 106/L and the cytogenetic study, which
was not obtained at the time of diagnosis, showed a com-
plex caryotype with del 5 and many break points in 5q3
and 5q33.
The endoscopy followed by bleeding was performed in
2008 when the platelet count was 837 × 109/L, haemoglo-
bin 113 g/L, PCV 35,2% and WBC 20.22 × 106/L. No
antithrombotic prophylaxis with LMWH was used. Anti-
platelet drug was withdraw seven days before endoscopy
and restarted one week after the procedure. Polyp size was
11x19 mm and it was located on right side of the colon.
Fourteen days after procedure the patient developed a
severe lower intestinal bleeding, which required RBC
transfusion; the bleeding was in the site of polypectomy
as demonstrated by arteriography; selective embolization
of the three branches of the ileo-colic artery resolve the
haemorrhage. It is noteworthy that in 2010 the patient
performed an aortic valve substitution complicated by a
local hemorrhagic complication which requested again
erythrocytes transfusion.
Discussion
Myeloproliferative neoplasms (MPN) are clonal haemato-
logical diseases, interesting mainly median-advanced age,
characterized by low rate of transformation into myelofi-
brosis and acute leukaemia but high risk of venous and
arterial thrombosis and of haemorrhages [10]. There is a
common belief that surgery could present an important
circumstantial risk factor for thrombosis and bleeding
[10], however, there are few available data on the inci-
dence of these complications after surgical intervention
in patient with MPN. On our best knowledge, no infor-
mation is available regarding the risk of bleedings after
endoscopic surgical procedures. The retrospective study
from the GIMEMA group [11] on 311 surgical proce-
dures in patients with polycythemia vera (PV) and essen-
tial thrombocythemia (ET) shows that the overall
incidence of bleeding after surgery is of about 10 %, with
a clear trend in subjects receiving antithrombotic prophy-
laxis and the hemorrhagic risk strongly related to the first
2 weeks of post-surgical period. Most of the patients
experienced major haemorrhages that required transfu-
sion treatment and prolonged hospital admission.
The use of aspirin to prevent thrombotic complica-
tions, which are the main causes of morbidity and mor-
tality in MPN, is largely shared [12] but it is a common
belief that aspirin has to be withheld one week before
elective surgical procedures. The patients must be
strictly followed for unpredictable development of
thrombotic or hemorrhagic derangement. In our patient,
despite the antiplatelet drug has been resumed 8 days
after the procedure, a major bleeding occurred. We
want to draw attention on the “window” period that fol-
lows endoscopic polypectomy. The delayed haemorrhage
we observed suggest to strictly control the patient for a
longer period than only one week. There are some
patients in whom current guidelines do not apply and
our case stress the importance of MPN as a risk factor
for complications of endoscopic polypectomy. These
evaluation should be considered also in medico-legal
context where claims of malpractice could arise in case
of thrombotic or haemorrhagic complications [13].
Conclusion
In conclusion, in patients using antiplatelet drugs, sur-
geries involving mucous tissues, i.e. endoscopy polypect-
omy, has to be taken in due account because they may
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represent a relevant cause of delayed bleeding as the
present case report shows.
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